| FavId-06
| Principal Investigator: |
Ilan Shapira, MD |
| Time frame of study: |
Ongoing |
| Location of Study: |
Beth Israel Medical Center |
| Contact: |
Continuum Cancer Research Program
(212) 844-6286
Ask for Study Coordinator Tahir Mirzoyev or Research Nurse Margaret
Dietrich.
|
Summary:
This is a phase III, randomized, double blind, placebo-controlled trial
which compares the time to progression of the disease (TTP) in patients
receiving FavId vaccine, the study medication, and Leukine to the TTP
in patients receiving a placebo and Leukine.
Eligibility:
This trial will be conducted in individuals with follicular B-cell lymphoma
(Grade 1, 2, or 3 by the WHO classification) 18 years of age and older.
Participans must not have received more than two prior treatment regimens
for NHL and must be at least 4 weeks between the last administration of
any prior chemotherapy, immunotherapy, radiotherapy or experimental therapy
and day 1 of rituximab administered on study. All patients must be stable
or responding to treatment with rituximab before randomization.
In addition, participants must be disease-free of any serious non-malignant
disease (e.g., psychiatric disorders, compromised pulmonary function,
congestive heart failure, or active bacterial, viral, or fungal infections).
|